Effects of indoleamine 2,3-dioxygenase inhibitor in non-Hodgkin lymphoma model mice

详细信息    查看全文

• 作者：Nobuhiko Nakamura ; Takeshi Hara ; Masahito Shimizu…
• 关键词：Indoleamine 2 ; 3 ; dioxygenase ; 1 ; methyl ; tryptophan ; Cyclophosphamide ; Non ; Hodgkin lymphoma ; Regulatory T cells
• 刊名：International Journal of Hematology
• 出版年：2015
• 出版时间：September 2015
• 年：2015
• 卷：102
• 期：3
• 页码：327-334
• 全文大小：834 KB
• 参考文献：1.Whiteside TL. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol. 2006;16:3-5.CrossRef PubMed
  2.Gajewski TF. Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment. Clin Cancer Res Off J Am Assoc For Cancer Res. 2006;12:2326s-0s.CrossRef
  3.Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest. 2007;117:1147-4.PubMed Central CrossRef PubMed
  4.Takikawa O. Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated l -tryptophan metabolism. Biochem Biophys Res Commun. 2005;338:12-.CrossRef PubMed
  5.Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med. 2002;196:459-8.PubMed Central CrossRef PubMed
  6.Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med. 1999;189:1363-2.PubMed Central CrossRef PubMed
  7.Yoshikawa T, Hara T, Tsurumi H, Goto N, Hoshi M, Kitagawa J, et al. Serum concentration of l -kynurenine predicts the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP. Eur J Haematol. 2010;84:304-.CrossRef PubMed
  8.Ninomiya S, Hara T, Tsurumi H, Hoshi M, Kanemura N, Goto N, et al. Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP. Ann Hematol. 2011;90:409-6.CrossRef PubMed
  9.Ninomiya S, Hara T, Tsurumi H, Goto N, Saito K, Seishima M, et al. Indoleamine 2,3-dioxygenase expression and serum kynurenine concentrations in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2012;53:1143-.CrossRef PubMed
  10.Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med. 2005;11:312-.CrossRef PubMed
  11.Yoshida N, Ino K, Ishida Y, Kajiyama H, Yamamoto E, Shibata K, et al. Overexpression of indoleamine 2,3-dioxygenase in human endometrial carcinoma cells induces rapid tumor growth in a mouse xenograft model. Clin Cancer Res Off J Am Assoc For Cancer Res. 2008;14:7251-.CrossRef
  12.Inaba T, Ino K, Kajiyama H, Yamamoto E, Shibata K, Nawa A, et al. Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma. Gynecol Oncol. 2009;115:185-2.CrossRef PubMed
  13.Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson M, et al. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res. 2007;67:792-01.CrossRef PubMed
  14.Kim KJ, Kanellopoulos-Langevin C, Merwin RM, Sachs DH, Asofsky R. Establishment and characterization of BALB/c lymphoma lines with B cell properties. J Immunol. 1979;122:549-4.PubMed
  15.Fujigaki S, Saito K, Takemura M, Fujii H, Wada H, Noma A, et al. Species differences in l -tryptophan-kynurenine pathway metabolism: quantification of anthranilic acid and its related enzymes. Arch Biochem Biophys. 1998;358:329-5.CrossRef PubMed
  16.Hoshi M, Saito K, Hara A, Taguchi A, Ohtaki H, Tanaka R, et al. The absence of IDO upregulates type I IFN production, resulting in suppression of viral replication in the retrovirus-infected mouse. J Immunol. 2010;185:3305-2.CrossRef PubMed
  17.Katz JB, Muller AJ, Prendergast GC. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev. 2008;222:206-1.CrossRef PubMed
  18.Tas SW, Vervoordeldonk MJ, Hajji N, Schuitemaker JH, van der Sluijs KF, May MJ, et al. Noncanonical NF-kappaB signaling in dendritic cells is required for indoleamine 2,3-dioxygenase (IDO) induction and immune regulation. Blood. 2007;110:1540-.CrossRef PubMed
  19.Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol Official J Am Soc Clin Oncol. 2005;23:5027-3.CrossRef
  20.Bocchia M, Defina M, Aprile L, Sicuranza A. Peptide vaccines for hematological malignancies: a missed promise? Int J Hematol. 2014;99:107-6.CrossRef PubMed
  21.Fujiwara H. Adoptive T-cell therapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors. Int J Hematol. 2014;99:123-1.CrossRef PubMed
  22.Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med. 2003;9:1269-4.CrossRef PubMed
  23.Godin-Ethier J, Hanafi LA, Piccirillo CA, Lapo
• 作者单位：Nobuhiko Nakamura (1)
  Takeshi Hara (1)
  Masahito Shimizu (1)
  Ryoko Mabuchi (1)
  Junji Nagano (1)
  Tomohiko Ohno (1)
  Takahiro Kochi (1)
  Masaya Kubota (1)
  Yohei Shirakami (1)
  Naoe Goto (1)
  Hiroyasu Ito (2)
  Kuniaki Saito (3)
  Takuji Tanaka (4)
  Hisataka Moriwaki (1)
  Hisashi Tsurumi (1)
  
  1. First Department of Internal Medicine, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan
  2. Department of Informative Clinical Medicine, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan
  3. Human Health Sciences, Graduate School of Medicine and Faculty of Medicine, Kyoto University, 46-29 Yoshida-Shimo-Adachi-cho, Sakyo-ku, Kyoto, 606-8501, Japan
  4. The Tohkai Cytopathology Institute: Cancer Research and Prevention (TCI-CaRP), 5-1-2 Minami-Uzura, Gifu, 500-8285, Japan
  
• 刊物主题：Hematology; Oncology;
• 出版者：Springer Japan
• ISSN：1865-3774

文摘

Indoleamine 2,3-dioxygenase (IDO) catalyzes the rate-limiting step in the metabolism of tryptophan along the kynurenine pathway. In tumors, increased IDO activity inhibits proliferation and induces apoptosis of T cells and natural killer cells. We investigated the therapeutic potential of IDO inhibitor 1-methyl-d-tryptophan (d-1MT) with cyclophosphamide (CY) in a mouse model of lymphoma. To examine the effect of d-1MT, mice were killed on day 28. Serum concentrations of l-kynurenine and l-tryptophan were measured by high-performance liquid chromatography. Regulatory T cells (Tregs) were counted by flow cytometry, and mRNA expressions of IDO1, Foxp3, IFN-γ, and COX-2 were examined by quantitative real-time reverse transcription-polymerase chain reaction. d-1MT+CY combination treatment significantly inhibited tumor growth as compared to either treatment alone. There were no significant differences in the serum l-kynurenine/l-tryptophan ratio or the IDO1 expression level in the tumors among the treatment groups. The expression levels of IFN-γ and COX-2 mRNA in tumor-draining lymph nodes (TDLNs) were found to be significantly up-regulated in the CY and d-1MT+CY groups. The number of Tregs in TDLNs in the d-1MT+CY group was significantly lower than that in CY groups on day 17. These results suggest that d-1MT in combination with CY is an effective treatment for lymphoma in a mouse model. Keywords Indoleamine 2,3-dioxygenase 1-methyl-tryptophan Cyclophosphamide Non-Hodgkin lymphoma Regulatory T cells